OBJECTIVES: To investigate the relationship between total estradiol (E2) levels and 9-year mortality in older postmenopausal women not taking hormone replacement therapy (HRT). DESIGN: Population-based study of persons living in the Chianti geographic area (Tuscany, Italy). SETTING: Community. PARTICIPANTS: A representative sample of 509 women aged 65 and older with measures of total E2. MEASUREMENTS: Serum total E2 was measured at the University of Parma using ultrasensitive radioimmunoassay (RIA). RESULTS: Women who died (n=135) during 9 years of follow up were older; had higher total E2 levels; and were more likely to have evidence of stroke, hypertension, diabetes mellitus, and congestive heart failure at baseline than survivors. Higher E2 levels were associated with a greater likelihood of death (hazard ratio (HR)=1.03, 95% confidence interval (CI)=1.01-1.06), and the relationship was independent of age, waist:hip ratio, C-reactive protein, education, cognitive function, physical activity, caloric intake, smoking, and chronic disease (HR=1.08 pg/mL, 95% CI=1.03-1.13, P=.003). The excessive risk of death associated with higher total E2 was not attenuated after adjustment for total testosterone (HR=1.12, 95% CI=1.02-1.18, P<.001) and after further adjustment for insulin resistance evaluated using the homeostasis model assessment (HR=1.07, 95% CI=1.03-1.17, P<.001). Total E2 was highly predictive of death after more than 5 years (HR=1.42: CI 1.01-1.91, P=.04) and not predictive of death for less than 5 years (P=.78). CONCLUSION: Higher total E2 concentration predicts mortality in older women not taking HRT.
OBJECTIVES: To investigate the relationship between total estradiol (E2) levels and 9-year mortality in older postmenopausal women not taking hormone replacement therapy (HRT). DESIGN: Population-based study of persons living in the Chianti geographic area (Tuscany, Italy). SETTING: Community. PARTICIPANTS: A representative sample of 509 women aged 65 and older with measures of total E2. MEASUREMENTS: Serum total E2 was measured at the University of Parma using ultrasensitive radioimmunoassay (RIA). RESULTS:Women who died (n=135) during 9 years of follow up were older; had higher total E2 levels; and were more likely to have evidence of stroke, hypertension, diabetes mellitus, and congestive heart failure at baseline than survivors. Higher E2 levels were associated with a greater likelihood of death (hazard ratio (HR)=1.03, 95% confidence interval (CI)=1.01-1.06), and the relationship was independent of age, waist:hip ratio, C-reactive protein, education, cognitive function, physical activity, caloric intake, smoking, and chronic disease (HR=1.08 pg/mL, 95% CI=1.03-1.13, P=.003). The excessive risk of death associated with higher total E2 was not attenuated after adjustment for total testosterone (HR=1.12, 95% CI=1.02-1.18, P<.001) and after further adjustment for insulin resistance evaluated using the homeostasis model assessment (HR=1.07, 95% CI=1.03-1.17, P<.001). Total E2 was highly predictive of death after more than 5 years (HR=1.42: CI 1.01-1.91, P=.04) and not predictive of death for less than 5 years (P=.78). CONCLUSION: Higher total E2 concentration predicts mortality in older women not taking HRT.
Authors: Kathryn H Schmitz; Hui Lin; Mary D Sammel; Clarissa R Gracia; Deborah B Nelson; Shiv Kapoor; Tracey L DeBlasis; Ellen W Freeman Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-09-28 Impact factor: 4.254
Authors: Kathryn M Rexrode; JoAnn E Manson; I-Min Lee; Paul M Ridker; Patrick M Sluss; Nancy R Cook; Julie E Buring Journal: Circulation Date: 2003-09-15 Impact factor: 29.690
Authors: Marc J Gunter; Donald R Hoover; Herbert Yu; Sylvia Wassertheil-Smoller; Thomas E Rohan; JoAnn E Manson; Barbara V Howard; Judith Wylie-Rosett; Garnet L Anderson; Gloria Y F Ho; Robert C Kaplan; Jixin Li; Xiaonan Xue; Tiffany G Harris; Robert D Burk; Howard D Strickler Journal: Cancer Res Date: 2008-01-01 Impact factor: 12.701
Authors: Rowan T Chlebowski; Jean Wactawski-Wende; Cheryl Ritenbaugh; F Allan Hubbell; Joao Ascensao; Rebecca J Rodabough; Carol A Rosenberg; Victoria M Taylor; Randall Harris; Chu Chen; Lucile L Adams-Campbell; Emily White Journal: N Engl J Med Date: 2004-03-04 Impact factor: 91.245
Authors: JoAnn E Manson; Judith Hsia; Karen C Johnson; Jacques E Rossouw; Annlouise R Assaf; Norman L Lasser; Maurizio Trevisan; Henry R Black; Susan R Heckbert; Robert Detrano; Ora L Strickland; Nathan D Wong; John R Crouse; Evan Stein; Mary Cushman Journal: N Engl J Med Date: 2003-08-07 Impact factor: 91.245
Authors: B Delia Johnson; Kathleen M Dwyer; Frank Z Stanczyk; Vera Bittner; Sarah L Berga; Glenn D Braunstein; Ricardo Azziz; YuChing Yang; Georgina E Hale; C Noel Bairey Merz Journal: J Clin Endocrinol Metab Date: 2010-06-16 Impact factor: 5.958
Authors: Gail A Laughlin; Joachim H Ix; Kevin Cummins; Matthew A Allison; Lori B Daniels Journal: Clin Endocrinol (Oxf) Date: 2012-09 Impact factor: 3.478
Authors: Marcello Maggio; Gian Paolo Ceda; Fulvio Lauretani; Stefania Bandinelli; Anna Maria Corsi; Francesco Giallauria; Jack M Guralnik; Giovanni Zuliani; Chiara Cattabiani; Stefano Parrino; Fabrizio Ablondi; Elisabetta Dall'aglio; Graziano Ceresini; Shehzad Basaria; Luigi Ferrucci Journal: J Clin Endocrinol Metab Date: 2011-01-14 Impact factor: 5.958